Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00772824
Recruitment Status : Unknown
Verified August 2009 by Banaras Hindu University.
Recruitment status was:  Recruiting
First Posted : October 15, 2008
Last Update Posted : August 11, 2009
Information provided by:
Banaras Hindu University

Brief Summary:
Glutamine, a non essential branched chain amino acid, is most important non toxic nitrogen carrier in body. It participates in variety of physiological functions. It is a major fuel source of enterocytes and is a substrate for gluconeogenesis in kidney, lymphocytes, and monocytes. It is also a nutrient in muscle protein metabolism in response to infection, inflammation and muscle trauma. The significance of glutamine to metabolic homeostasis becomes evident during periods of stress, when it becomes a conditionally essential amino acid. Role of glutamine as protective agent in hepato-biliary dysfunction, in maintaining mucosal integrity of the Gastrointestinal tract following its administration in patient with major bowel surgery as a supplement and part of TPN in critically ill patients and in patients of septicemia, is well established. However the role of glutamine supplementation in reducing or preventing chemotherapeutic agents induced toxicity in cancer patients is controversial.

Condition or disease Intervention/treatment Phase
Breast Cancer Dietary Supplement: Glutamine Dietary Supplement: IV Glutamine Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial
Study Start Date : December 2007
Estimated Primary Completion Date : September 2009
Estimated Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Glutamine
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: 1
10 patients (30 cycles) of chemotherapy will receive placebo
Active Comparator: 2
Intravenous glutamine
Dietary Supplement: IV Glutamine
50 ml of 20% glutamine IV before chemotherapy
Experimental: 3
Oral Glutamine
Dietary Supplement: Glutamine
2g/kg body weight twice daily in divided doses for 5 days

Primary Outcome Measures :
  1. Reduction in toxicity [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Serum level of creatinine kinase and LDH [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patients > 18 years of age
  • Histologically or cytologically proven breast cancer
  • Receiving CEF chemotherapy cycles presently or in the past
  • The patients who will give informed consent to participate in the study
  • Patients must have sufficient organ and marrow function
  • Stage 1 neuropathy, subclinical neuropathy, surgery induced neuropathy

Exclusion Criteria:

  • Pregnancy
  • Clinical/biochemical severe liver failure
  • Clinical/biochemical severe renal dysfunction
  • Refusal to participate in the study
  • Patients who have received prior chemotherapy with paclitaxel.
  • Patients who have neuropathy due to any known systemic or metabolic causes like diabetes, leprosy, nutritional deficiency induced (vit. B12) etc

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00772824

Contact: Manoj Pandey, MS 915422309511
Contact: Deepika Joshi, MD, DM 915422307576

Sir Sunder Lal Hospital Recruiting
Varanasi, UP, India, 221005
Contact: Manoj Pandey, MS    915422309511   
Principal Investigator: R K Goel, MD         
Sponsors and Collaborators
Banaras Hindu University
Principal Investigator: R K Goel, MD Institute of Medical Sciences


Responsible Party: Dr. Manoj Pandey, Head, Surgical Oncology, Institute of Medical Sciences Identifier: NCT00772824     History of Changes
Other Study ID Numbers: GLU_07
First Posted: October 15, 2008    Key Record Dates
Last Update Posted: August 11, 2009
Last Verified: August 2009

Keywords provided by Banaras Hindu University:
Breast cancer
FEC chemotherapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases